Mon, Sep 22, 2014, 2:20 AM EDT - U.S. Markets open in 7 hrs 10 mins


% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

speedrunner199 3 posts  |  Last Activity: Sep 10, 2014 1:56 AM Member since: Aug 6, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to


    by tonyd58 Sep 10, 2014 1:31 AM
    speedrunner199 speedrunner199 Sep 10, 2014 1:56 AM Flag

    You are an idiot!
    That's what the shorts have been saying for the past 3 months and they have been wrong all the way from 65 to 110.
    I can't predict whether it will go to low 90's or not but I am quite certain the GILD will reach 120 sometime within the next few month, with FDA approval, TAF data and Q3 earnings expected by October. Moreover, 130-150 will be reached sometime in 2015- following record sales for the combo therapy and the advancement of TAF- the new standard for HIV therapy.
    You can gamble or you can invest in the best biotech company with great pipeline and execution.

    Sentiment: Strong Buy

  • Reply to

    sell off absolute stupidity

    by sexystk99 Sep 7, 2014 5:11 PM
    speedrunner199 speedrunner199 Sep 7, 2014 6:45 PM Flag

    It was a very good opportunity to buy.

    I was fortunate to add near the lows.

    Based on the future earnings p/e ratio, can easily justify 15-20 p/e ratio, which would put the price between $150-200 (assuming $10/share earnings in 2015).

    Great long-term hold.

  • Allianz's Analyst Likes Biogen Idec Inc, Celgene Corporation & Gilead
    5:28p ET September 6, 2014 (Benzinga) Print
    John Schroer of Allianz Global Investors spoke on CNBC's Fast Money about the biotech stocks he likes.

    He said that his first pick would be Biogen Idec Inc (NASDAQ: BIIB), which is a leading company in the multiple sclerosis space. He thinks that the company will have 20 to 25 percent earnings growth over the next three years, and it has a valuation of 25 times earnings.

    The biotech stock sold off on Friday on the news about potential pricing pressure on Gilead's (NASDAQ: GILD) hepatitis C medicine. Schroer thinks that Gilead is a great stock, trading at 11 times earnings, with a strong growth potential that could easily trade at $200 billion market capitalization.

    Celgene Corporation (NASDAQ: CELG) has also found its place on the list of stocks in the biotech space that John Schroer would buy. Celgene fell 0.15 percent on Friday, and it closed at $93.79.

1.30-0.05(-3.70%)Sep 19 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.